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Abstract
It is controversial whether mitochondrial dysfunction in skeletal
muscle is the cause or consequence of metabolic disorders. Herein,
we demonstrate that in vivo inhibition of mitochondrial ATP
synthase in muscle alters whole-body lipid homeostasis. Mice with
restrained mitochondrial ATP synthase activity presented intrafiber
lipid droplets, dysregulation of acyl-glycerides, and higher visceral
adipose tissue deposits, poising these animals to insulin resistance.
This mitochondrial energy crisis increases lactate production,
prevents fatty acid b-oxidation, and forces the catabolism of
branched-chain amino acids (BCAA) to provide acetyl-CoA for de
novo lipid synthesis. In turn, muscle accumulation of acetyl-CoA
leads to acetylation-dependent inhibition of mitochondrial respira-
tory complex II enhancing oxidative phosphorylation dysfunction
which results in augmented ROS production. By screening 702
FDA-approved drugs, we identified edaravone as a potent mito-
chondrial antioxidant and enhancer. Edaravone administration
restored ROS and lipid homeostasis in skeletal muscle and rein-
stated insulin sensitivity. Our results suggest that muscular mito-
chondrial perturbations are causative of metabolic disorders and
that edaravone is a potential treatment for these diseases.
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Introduction
Obesity is a complex chronic condition that affects all organ systems
and increases the rate of premature mortality (Spiegelman & Flier,
2001; Stefan et al, 2017). Increased visceral white adipose tissue
(v-WAT) is associated with elevated blood levels of nonesterified
free fatty acid (FFA), which in turn may result in insulin resistance
(IR) in peripheral insulin target tissues such as skeletal muscle
(Skm) (Despres & Lemieux, 2006). Moreover, WAT and Skm are
endocrine organs that release and respond to hormones, a function
that contributes to chronic inflammation associated with metabolic
diseases (Pedersen & Febbraio, 2012; Stanford et al, 2015; Ciaraldi
et al, 2016).
Interest in a role for mitochondria in the setting of metabolic
disorders has increased in response to growing evidence linking
mitochondrial dysfunction with pathology (Friedman & Nunnari,
2014; Shadel & Horvath, 2015; Kauppila et al, 2017). Mitochondria
are essential in maintaining cell homeostasis by controlling bioener-
getics, immunity, intracellular signaling, and cell death (Spinelli &
Haigis, 2018). Furthermore, these organelles are involved in coordi-
nating cellular adaptation to stressors and nutrient availability, and
regulating glucose, amino acid, and lipid metabolism (Liesa & Shiri-
hai, 2013; Vyas et al, 2016; Garcia-Bermudez et al, 2018). Depend-
ing on the disposal of ATP, TCA intermediates, and reduced
coenzymes (NADH, FADH2), different intramitochondrial dehydro-
genases transfer electrons to the respiratory complexes of the elec-
tron transport chain (ETC) to generate the proton electrochemical
gradient used for ATP synthesis in oxidative phosphorylation
(OXPHOS). Since Skm is the largest oxidative and insulin-sensitive
organ in mammals, understanding this mitochondrial-mediated
metabolic flexibility may reveal new therapeutic strategies for
diseases characterized by whole-body dysregulation of glucose and
lipid metabolism.
Structural and functional perturbations in Skm mitochondria
have been associated with the onset and complications of metabolic
diseases (Kelley et al, 2002; Lowell & Shulman, 2005; Sivitz &
Yorek, 2010; Hesselink et al, 2016). Reduced OXPHOS gene and
protein expression has been described in response to genetic and
nutritional obesity (Mootha et al, 2003; Patti et al, 2003; Sparks
et al, 2005; Wang et al, 2010). In fact, a reduction of up to 40% in
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the expression and activities of Skm respiratory complexes has been
reported in T2D subjects (Kelley et al, 2002; Ritov et al, 2005;
Formentini et al, 2017a). Skm from the same T2D individuals
presented diminished-size fissioned mitochondria, particularly in
subsarcolemmal fractions (Ritov et al, 2005), indicating perturba-
tions in mitochondrial dynamics. Additionally, hereditable Skm
mitochondrial dysfunctions have been identified by NMR spec-
troscopy in vivo, unveiling OXPHOS and TCA defects in offspring of
T2D subjects (Petersen et al, 2005; Befroy et al, 2007).
A key unanswered question is whether the mitochondrial alter-
ations observed in Skm from T2D subjects are secondary features of
the dyslipidaemic environment or participate in the setting of dyslip-
idaemia. In fact, the exact mechanism linking mitochondrial activity
with obesity and T2D remains to be clarified.
A pivotal regulator of mitochondrial function is the ATP
synthase, an inner membrane (IMM) enzyme at the crossroads of
bioenergetics, apoptosis, redox metabolism, and the shape of cristae
(Sanchez-Arago et al, 2013; Spinelli & Haigis, 2018). In this study,
we demonstrate that its activity plays a key role as a transducer in
lipid metabolism. The in vivo inhibition of Skm ATP synthase trig-
gers lipogenic reprogramming to an increased lipid synthesis in both
muscle and WAT, causing these animals to develop T2D faster upon
feeding them a high-fat diet (HFD). In vivo treatment with the mito-
chondrial enhancer edaravone restored lipid and glucose homeosta-
sis in mice. Hence, we propose that mitochondrial activity is a key
regulator of skeletal muscle metabolism and endocrine signaling.
Results
A mouse model for the in vivo impairment of Skm OXPHOS
In order to assess the role of OXPHOS on the pathophysiology of Skm
lipid metabolism, we generated an inducible and tissue-specific mouse
model that expressed the active form (Boreikaite et al, 2019) of the
human ATP synthase inhibitor ATPIF1H49K (Formentini et al, 2014) in
striatal muscle. Double transgenic Tet-On mice ATPIF1H49K|
T/H
(Fig 1A) express ATPIF1H49K in ACTA-1-positive myocytes (Fig 1B–
D), while no expression was observed in the brain, liver, or WAT
(Fig 1D). Interestingly, the endogenous expression of mouse-ATPIF1
in Skm was not detectable (Fig 1D). O2 consumption rate (OCR) in
isolated mitochondria from Skm confirmed that state 3 (ADP-stimu-
lated) but not uncoupled (FCCP-induced) respiration was signifi-
cantly inhibited in ATPIF1H49K|
T/H mice when compared to that in
control mice (Fig 1E), suggesting that the ATPIF1H49K effect was
specific to ATP synthase. However, the reduction in total O2
consumption (Fig 1E, left panel) indicated a lower mitochondrial
respiration in ATPIF1H49K|
T/H mice (referred to from now on as
LowOXPHOS mice).
We next sought to unveil the impact of limiting OXPHOS on the
Skm proteome by performing iTRAQ quantitative proteomics on
hindlimb muscles from wt and LowOXPHOS mice (Figs 1F–K, and
EV1 and EV2). Of the 1,250 proteins identified, 2.1% were signifi-
cantly downregulated and 7.7% were upregulated in LowOXPHOS
fibers compared to their expression in fibers from wt animals
(Fig 1F–H). Gene Set Enrichment (GSEA) bioinformatic analysis of
the results revealed that 14 metabolic pathways were perturbed
when OXPHOS was inhibited (Figs 1I and J, and EV1 and EV2). The
related enrichment scores (ES and NES) were particularly significant
for the redox system, lipid metabolism, BCAA catabolism, and FAD-
binding proteins (Fig 1J). Remarkably, the Skm iTRAQ LowOXPHOS/
wt ratio for most of the lipid oxidation and BCAA catabolism
enzymes was significantly upregulated (Figs 1K, and EV1 and EV2).
Skm-restrained OXPHOS alters lipid contents and metabolism
In line with the possible alterations in lipid metabolism, the
LowOXPHOS mouse body weight was higher than in wt mice (Figs 2A
and EV3A). Moreover, the hindlimb muscles of the transgenic mice,
particularly the soleus oxidative muscle, were significantly whiter
than the control (Fig 2B) due to a higher intramuscular infiltration of
adipocytes (Fig 2C and D). Accordingly, the iTRAQ ratio (Fig 2E) and
WB expression (Fig 2F) of Skm proteins related to lipid synthesis
were higher in LowOXPHOS mice compared to wt littermates. In partic-
ular, expression in muscle of the lipogenic enzymes ATP citrate lyase
(ACLY) and fatty acid synthase (FASN) was 130 and 210%, respec-
tively, upregulated in mice with restrained OXPHOS (Fig 2F), suggest-
ing altered de novo lipogenesis. Intriguingly, in LowOXPHOS mice
ACLY resulted highly acetylated, what has been related to the stabi-
lization and activation of the protein, promoting lipid biosynthesis
[(Lin et al, 2013), Fig 2G]. Consistently, we found that acetyl-CoA
accumulated in Skm of LowOXPHOS mice (Fig 2H). In Skm mitochon-
dria, acetyl-CoA is preferentially generated as the end product of
glucose metabolism, free fatty acid (FFA) b-oxidation, or BCAA cata-
bolism (Pietrocola et al, 2015; Fig 2I). In order to unveil the primary
source for acetyl-CoA accumulation in LowOXPHOS mice, we first
investigated glucose metabolism. As previously reported (Formentini
et al, 2012), the inhibition of mitochondrial ATP production (Fig 1E)
caused a rewiring of energy metabolism through an increased aerobic
glycolysis (Figs 2J and EV3B), with the aim to maintain Skm ATP
levels (Fig EV3C). However, despite a slight increase in glucose
uptake (Fig 2K), ATPIF1H49K expressing myocytes showed a reduced
total oxidation of 14C(u)-glucose to CO2 in comparison to controls
(Fig 2L). This could be due to the role of acetyl-CoA as a metabolic
sensor able to allosterically inactivate enzymes involved in its synthe-
sis, such as the pyruvate dehydrogenase complex (PDH) (Pietrocola
et al, 2015). Accordingly, we found that PDH was phosphorylated in
LowOXPHOS mice (Fig 2M), and pyruvate was rerouted to lactate
production (Fig 2N), thus ruling out glycolysis as the main source of
acetyl-CoA during OXPHOS inhibition.
The de novo lipid synthesis intermediate malonyl-CoA is
known to limit FFA degradation (Foster, 2012; Fig 2I). In line
with this and with a previous report in human myotubes (For-
mentini et al, 2017a), FFA b-oxidation resulted in a 35% inhibi-
tion in myocytes derived from LowOXPHOS compared to those in
wt mice (Fig 2O). This thus suggests that enhanced Skm BCAA
utilization or other minor pathway fluxes [such as reductive
glutaminolysis (Liu et al, 2016)] are responsible for the observed
acetyl-CoA accumulation.
As a result of increased lipid synthesis along with a decrease in
their catabolism, FFAs accumulated in muscle (Fig 2P). Because this
dysregulation was accompanied by an increase in Skm glycerol
levels (Fig EV3D), we thus reasoned that these events might
contribute to altered intramuscular neutral lipid storages.
Accordingly, optic (Fig 2Q and R) and electron microscopy (Fig 2S)
images showed the presence of lipid droplets (LD; Fig 2Q–S) inside
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the oxidative polygonal myofibers of the soleus (Fig 2R) from
LowOXPHOS but not wt mice.
To confirm the direct relationship between ATPIF1H49K and LD
formation, we overexpressed the human protein in mouse C2C12
myocytes (Fig 2T). The resulting inhibition of the ATP synthase
activity during starvation and palmitate supplementation triggered
the development of a higher number of BODIPY-positive LDs in
comparison to the control (Figs 2T and EV3E). Similar results were
obtained by the pharmacological inhibition of the ATP synthase
(5 lM oligomycin, Figs 2U and EV3F), indicating that this is a
general trait of inhibiting CV. Interestingly, we did not find changes
in the expression of proteins from mTOR or autophagy pathways in
LowOXPHOS mice (Fig EV3G and H), suggesting that these processes
are not involved. However, further studies would be required to
exclude their participation in the observed lipogenesis.
In order to verify if lipid synthesis and accumulation upon
OXPHOS inhibition may be related to augmented BCAA catabolism,
we performed the same experiment in BCAA-free media (containing
other AAs and palmitate as biosynthetic substrates). Upon this
condition, no differences in LD formation were observed in the pres-
ence or absence of the ATP synthase inhibitor (Fig 2T). In line with
this hypothesis, plasma levels of BCAA were augmented in
LowOXPHOS mice compared to wt (Fig 3A), and the uptake of 14C(u)-
leucine or 14C(u)-isoleucine increased in myocytes expressing
ATPIF1H49K (Fig 3B). Interestingly, no differences in the Skm BCAA
amounts were detected between the two genotypes (Fig 3C), suggest-
ing an increase in BCAA muscular catabolism in LowOXPHOS mice.
Consistently, in this situation, 14C(u)-BCAA oxidation to CO2 was
increased compared to control (Fig 3D). Moreover, when myocytes
were administrated with 14C(u)-leucine or 14C(u)-isoleucine and the
lipid fraction extracted, a higher concentration of C14-lipids was
observed upon OXPHOS inhibition (Fig 3E), what suggests a higher
BCCA catabolism and incorporation into lipids in LowOXPHOS mice.
Mitochondrial-driven rewiring of Skm lipid and BCAA metabolism
signals a hyperlipidemic phenotype
Despite the observed ATP synthase-dependent lipid dysregulation in
muscle, the transgenic mice did not present alterations in blood
glucose levels (Fig EV3I) or in tissue insulin or glucose sensitivity
(Fig EV3J). Therefore, we next investigated the possibility that feed-
ing animals a HFD may potentiate the phenotype in LowOXPHOS
mice. After 60 days of HFD, the structure of Skm myofibers was
altered, and intramuscular adipocyte storage became elevated in
both wt and ATPIF1H49K-expressing mice (Fig 3F). However,
animals with restrained OXPHOS displayed a much stronger pheno-
type, with reduced soleus mass, shrinkage of fibers (Fig 3F,
arrows), and greater adipocyte infiltration (Fig 3F, left panels)
compared to those of wt animals. Therefore, we next sought to
disclose the impact of muscle mass perturbations on the motor func-
tion of LowOXPHOS mice. No significant alterations in rotarod
(Fig 3G) and open field (Figs 3H and EV3K) tests were noticed
between wt and LowOXPHOS animals; however, upon ATP synthase
inhibition mice displayed reduced performances in the grip force
test (Fig 3I).
Concomitantly to these alterations in motor patterns, LowOXPHOS
mouse weight was higher than that in control mice (Fig EV4A).
Despite no significant changes in mouse food intake were observed
between wt and LowOXPHOS mice (Fig EV4B), lipidomic analysis
revealed that at day 60 of HFD, the Skm lipidomic profile was
deeply altered (Fig 3J) as a consequence of ATP synthase inhibition.
In particular, the Skm levels of ceramides and DAGs, lipid species
related to the onset of IR (Szendroedi et al, 2014; Turpin-Nolan
et al, 2019), were increased 130% in LowOXPHOS mice in comparison
to levels in wt mice (Fig 3K). Consistent with our hypothesis, the
observed OXPHOS-dependent alteration in Skm lipid profile led to
elevated blood triglycerides (Fig 3L), and Skm showed reduced
expression of GLUT1 and PPARb/d (Fig 3M). Moreover, and consis-
tent with previous data in human myocytes derived from obese and
T2D subjects (Formentini et al, 2017a), Skm TNFa levels were
270% upregulated and the pattern of myokines and cytokines
altered when ATP synthase was inhibited (Fig 3N), what may
contribute to inflammation associated with the IR setting (Ciaraldi
et al, 2016). All these metabolic alterations led to the transgenic
animals being prone to developing metabolic diseases (Fig 3O and
P). Indeed, wt mice developed T2D at day 80–90 of HFD (Fig 3O),
while the blood glucose levels (Fig 3O) and the insulin (ITT) and
glucose (GTT) tolerance tests (Fig 3P) in LowOXPHOS mice indicated
◀ Figure 1. A mouse model for the in vivo inhibition of Skm OXPHOS.A PCR analysis of the human H49K variant of the ATPIF1 and rtTA constructs in wild-type (wt), ACTA1-rtTA (T), ATPIF1H49K-TRE (H) or double transgenic (T/H) mice.
B–D (B, D) WB expression of the human (h) or human + mouse (m + h) ATPIF1 protein in Skm (B, D), brain, liver, and WAT (D) extracts. hATPIF1 is only expressed in
Skm from ATPIF1H49K|
T/H mice. HSP60 and a-tubulin are shown as loading controls. n = 3 mice/genotype. (C) Immunofluorescent staining of wt and ATPIF1H49K|
T/H
hindlimb muscle slices with hATPIF1 and bF1 antibodies. Images are representative of 3 mice/genotype, 5 fields/mouse. hATPIF1 H49K is only expressed in T/H mice.
E Polarographic profiles of isolated mitochondria from wt (lower trace) and ATPIF1H49K|
T/H (upper trace) animals. Histograms show a reduction in state 3 respiration
consistent with the inhibition of ATP synthase in ATPIF1H49K|
T/H mice. Bars are the mean  SEM of n = 3 mice/genotype, 3 traces/mouse; OL, oligomycin; Ant A,
antimycin A.
F, G Quantitative proteomic analysis (iTRAQ) of hindlimb Skm from wt and LowOXPHOS mice. The pie charts (F) and volcano plot (G) present the upregulated
(log2[LowOXPHOS/wt] ≥ 1, red) or downregulated (log2[LowOXPHOS/wt] ≤ 1, blue) proteins. A ()log P-value of > 4 was considered statistically significant.
H Cytoscape representation of the most upregulated proteins in Skm from LowOXPHOS mice.
I Cytoscape representation of GSEA analysis. Fourteen significantly altered pathways and their normalized enrichment score (NES) are shown. 1. Hallmarks of
adipogenesis; 2. Go_Mitocondrial signal; 3. Kegg_TCA Cycle 4; Pyruvate Metabolism Reactome; 5. Hallmarks of OXPHOS; 6. Go_ETC; 7. Go_NADPH metabolism; 8.
Kegg_Propionate metabolism; 9. Redox system; 10. Kegg_BCAA catabolism; 11. Go_Lipid metabolism; 12. Kegg_Lipid oxidation; 13. NEFA, Tg and ketone bodies; 14.
Go_FAD-binding proteins. See also Fig EV1.
J Enrichment score (ES) graphs from GSEA analysis.
K Skm iTRAQ ratio of proteins from BCAA catabolism. Higher intensities of red or blue colors represent higher or lower LowOXPHOS/wt expression ratios, respectively.
Data information: (F–K) Data are the mean  SEM of n = 12 animals/genotype measured in 2 different iTRAQ analysis *P < 0.05 when compared to wt by ANOVA and
Student’s t-test. See also Figs EV1 and EV2.
Source data are available online for this figure.
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that T2D already occurred at day 60–70. Altogether, these experi-
ments show that Skm OXPHOS activity plays a key role in the main-
tenance of whole-body glucose homeostasis.
In order to better understand the metabolic mechanisms lead-
ing to the observed phenotype, we looked for differentially regu-
lated metabolic enzymes in our proteomic datasets. Interestingly,
we found that whereas the BCAA catabolism proteins were signif-
icantly upregulated in muscle (Figs 1K, and EV1 and EV2), the
WAT iTRAQ LowOXPHOS/wt ratio showed the opposite trend for
these same enzymes (Fig 4A). The increased Skm and inhibited
WAT catabolism of BCAAs is a recently described marker of IR
(Neinast et al, 2019). Consistently, odd fatty acids, which are
substrates of the same pathway, are reduced in Skm and accumu-
lated in WAT from restrained OXPHOS mice (Fig 4B). To note
that Skm-specific impairment of OXPHOS also altered de novo
lipid synthesis (Fig 4C) in WAT and modified the expression of
protein from FA availability, lipid transport, and metabolism
(Fig 4D). This may cause the weight of v-WAT to be higher in
LowOXPHOS than in wt mice (Figs 4E and EV4C). These results
suggest possible whole-body metabolic alterations or a mitochon-
drial-dependent cross-talk between muscle and adipose tissue
(Pedersen & Febbraio, 2012) that deserve further investigation.
Quantitative lipidomic analysis (Fig 4F) confirmed a significant
upregulation of total TAGs (Figs 4G and EV4D) and DAGs
(Figs 4G and EV4E) and saturated DAGs (Fig EV4F) in v-WAT
from LowOXPHOS mice compared to that in wt mice.
The lipogenic switch alters the redox system and lipid-related
OXPHOS components
The observed increase in saturated lipids in WAT (Fig EV4F) and
Skm (Figs 4H and EV4G) from mice with restrained OXPHOS raised
the possibility that augmented ROS production in these mice may
mediate these effects (Ayala et al, 2014; Shadel & Horvath, 2015).
Inhibition of ATP synthase triggers the accumulation of ROS in
cancer (Formentini et al, 2012). Indeed, in our model, mitochon-
drial ROS were 40% higher in myocytes expressing ATPIF1H49K than
levels in the control (Fig 4I). Moreover, the production of 4-hydro-
xynonenal (4HN), a marker of ROS-dependent lipid peroxidation
(Ayala et al, 2014), was augmented in Skm from LowOXPHOS mice
compared to that in wt mice (Fig 4J). Consistent with the role of
NADPH as a cofactor involved in detoxification of lipid ROS (Stock-
well et al, 2017) and as a result of the ROS cascade, we observed a
general alteration in the Redox system (Figs 4J and EV1) and
NADP/NADPH ratio (Fig EV5A) in these animals.
In order to unveil the mitochondrial site(s) of origin for ROS
production, we studied the direct effect of ATPIF1H49K on the
OXPHOS proteins and related systems. Consistent with the O2
consumption data (Fig 1E), no changes were observed in the Skm
expression of different subunits from the respiratory CI, CIII, CIV,
and CV between LowOXPHOS and wt genotypes (Fig 4K). However,
SDHA and SDHB, belonging to CII, and subunits from the electron
transfer flavoprotein ETF were significantly overexpressed upon
◀ Figure 2. Perturbations in Skm OXPHOS alter lipid metabolism and storage.Data for wild-type (wt, black bars and traces) and LowOXPHOS (orange bars and traces) mice are shown.
A Representative images of mice and body weight graph following the expression of mitochondrial ATPIF1H49K (days of doxycycline) (wt, n = 12; LowOXPHOS, n = 12).
B Representative images of hindlimb muscles. Arrows point to the soleus.
C, D Transversal slices of red fibers from soleus stained with hematoxylin/eosin (C). Higher im-WAT infiltrations in LowOXPHOS mice are shown. Quantifications in (D)
(wt, n = 6; LowOXPHOS, n = 6; 10 fields/mouse).
E, F iTRAQ ratio (E) and representative WB expression (F) of Skm proteins from de novo lipid synthesis. The expression of ATP citrate lyase (ACLY), acetyl-CoA carboxylase
(ACAC), fatty acid synthase (FASN) and their phosphorylation (p) are shown. Two samples per condition; each sample contains protein extracts from 3 mice. GAPDH
is shown as a loading control. Quantifications in lateral histograms (wt, n = 6; LowOXPHOS, n = 6). In (E), a higher intensity of red color represents a higher
LowOXPHOS/wt expression ratio.
G Immunocapture (IP) of Skm acetylated proteins blotted with anti-ACLY antibody.
H Skm acetyl-CoA amounts (wt, n = 8; LowOXPHOS, n = 8).
I Schematic representation of de novo FFA synthesis and the increase in LD. Elevated acetyl-CoA levels may be derived from dysregulation of the FFA b-oxidation,
glycolysis, or BCAA metabolism.
J Myocyte rates of aerobic glycolysis to lactate production. Bars are the mean  SEM of n = 3 experiments, 9 replicas/condition.
K, L 14C(u)-glucose uptake (K) and oxidation to CO2 (L) in myocytes expressing or not the ATP synthase inhibitor ATPIF1H49K. Bars are the mean  SEM of n = 3
experiments, 6 replicas/condition.
M Representative WB expression of Skm PDH and its phosphorylation. Two samples per condition; each sample contains extracts from 3 mice. Quantification in
histograms (wt, n = 6; LowOXPHOS, n = 6).
N Skm levels of lactate (wt, n = 6; LowOXPHOS, n = 6).
O FFA b-oxidation in primary cultures of myocytes derived from wt or LowOXPHOS mouse hindlimbs. Bars are the mean  SEM of n = 3 experiments, 9
replicas/condition.
P FFA amounts in Skm extracts (wt, n = 8; LowOXPHOS, n = 8).
Q, R Transversal slices of soleus stained with hematoxylin/eosin (Q). Arrows indicate LDs in LowOXPHOS mice. Oil Red O staining and enzymatic activity of respiratory CI
in transverse contiguous slices (R). Images are representative of n = 4 mice/genotype, 10 images/mouse. Note the colocalization of oxidative fibers with LDs (R).
S Electron microscopy of transversal slices of the soleus. Intrafiber LDs surrounded by mitochondria in LowOXPHOS mice are shown. Histogram shows the
quantifications of n = 4 animals/genotype, 10 images/animal.
T LD formation upon ATP synthase inhibition (ATPIF1H49K) in starved myocytes after 24 h of palmitate supplementation in the presence or absence of BCAA. Blue:
DAPI, nuclei; green: BODIPY-positive LDs. Histograms show the quantification expressed as the number of LDs/nuclei. Bars are the mean  SEM of n = 3
experiments, 12 fields/condition. See Fig EV3E.
U LD formation upon ATP synthase inhibition (5 lM oligomycin) in myocytes after 24 h of palmitate supplementation. Histograms show the quantification expressed
as fold of control of the BODIPY/DAPI fluorescence intensity. Seven fields/condition. See Fig EV3F.
Data information: Bars are the mean  SEM of the indicated (n) mice/genotype *P < 0.05 when compared to wt by ANOVA and Student’s t-test. See also Fig EV3.
Source data are available online for this figure.
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ATP synthase inhibition (Figs 4K, and EV5B and C). CII and the ETF
complex transfer electrons (e) from FADH2 to the ETC. Despite this
upregulation of CII and ETF proteins (Figs 4K, and EV5B and C), we
found an increase in the FAD system protein expression (Fig 4L)
and (FADH + FADH2)/FAD ratio (Fig 4M) in Skm from LowOXPHOS
mice, suggesting an inefficient oxidation of FADH2 in our system.
This could be partially explained by a limited mitochondrial respira-
tion upon ATP synthase inhibition, as well as by the accelerated
catabolism of BCAAs (Neinast et al, 2019) in Skm (Figs 1K and 3D,
and EV2) and the upregulation of proteins involved in the reduction
of FAD to FADH2 (Fig 4L).
Hindering the ATP synthase activity causes further OXPHOS
dysfunction and burst in ROS
FADH2 accumulation (Fig 4M) may also be a consequence of ETC
dysfunction that leads to ROS production (Shadel & Horvath, 2015).
To test this possibility, we first assessed CI enzymatic activity in
Skm isolated mitochondria. This analysis revealed no significant
changes between the two genotypes (Fig EV5D), consistent with the
absence of changes in the ETC activity of coupled Skm mitochondria
when electrons entered through CI (Fig 1E). We next assayed the
activity of CII, the entry point of FADH2 electrons into the ETC.
Surprisingly, despite a 2-fold higher expression of CII catalytic subu-
nits (Figs 4K, and EV5B and C) in LowOXPHOS mice, no differences
in CII activity were detected between wt and transgenic mice fed
with chow or HFD (Fig 5A). These results suggest that CII is not
functioning properly in the muscle of LowOXPHOS mice. This is
supported by the impaired maximum mitochondrial respiration
observed when using CII-specific respiratory substrates, such as
succinate or carnitine-palmitate (Fig 5B).
We next sought to understand the mechanisms underlying the
inhibition of CII. The activity of several subunits of ETC complexes
is regulated by post-translational modifications (Acin-Perez et al,
2011, 2014; Garcia-Bermudez et al, 2018). No changes in the
isoelectric point (pI) of the SDHB subunit of CII were detected
between the two genotypes (Fig 5C). However, the acidic shift in
the pI of the catalytic subunit SDHA in LowOXPHOS mice compared
to that in wt mice (Fig 5D) indicated an altered post-translational
modification of the protein that may regulate CII activity (Finley
et al, 2011). In particular, Skm from wt animals presented 5 pools
of SDHA that differed in the pI (6.5, 6.7, 6.8, 6.9 and 7.1), while
only the 2 more acidic pools (pI 6.5 and 6.7) were present in
LowOXPHOS mice (Fig 5D). Interestingly, when only the Skm acetyl-
K proteins were run into the gel, SDHA was only present in the two
more acidic pools (pI 6.5 and 6.7; Fig 5E), suggesting that the basic
pools (pI 6.8, 6.9, and 7.1) correspond to deacetylated forms of the
protein. Immunoprecipitation of SDHA (revealed with anti-acetyl-K
antibody) or acetyl-K proteins (revealed with anti-SDHA antibody)
in Skm isolated mitochondria from wt and LowOXPHOS mice con-
firmed that the protein was more acetylated upon ATP synthase
in vivo inhibition (Fig 5F). According to previous studies (Finley
et al, 2011) and acetylation data from databases [PhosphositePlus,
V6.5.8; (Hornbeck et al, 2015)], at least six acetylation sites on
murine SDHA are directly related to CII activity, corresponding to
K179 and K182 from the FAD-binding domain and K485, K498,
K598, and K608 from the succinate dehydrogenase flavoprotein
domain (Fig 5G and H).
CII is also a known site of ROS production (Yankovskaya et al,
2003). In order to demonstrate whether the dysregulation in CII
activity is causal for the observed increase in ROS in LowOXPHOS
mice, we treated ATPIF1H49K expressing myocytes with specific ETC
inhibitors (Fig 5I). As expected, both rotenone and antimycin A,
inhibiting CI and CIII respectively, increased ROS production
(Fig 5I). However, the treatment of the ATPIF1H49K cultures with
malonate, a known inhibitor of CII, reverted ROS amounts to the
levels of wt (Fig 5I), indicating a direct participation of CII in the
generation of ROS upon ATP synthase inhibition (Fig 5I). Malonate
is known to inhibit CII at flavin site (Quinlan et al, 2012). To under-
stand if ROS from CII arose only from the flavin site, we repeated
the experiment with carboxin, that inhibits CII at the ubiquinone-
binding site (Quinlan et al, 2012). Interestingly, only malonate but
◀ Figure 3. OXPHOS-mediated alterations in lipid and amino acid metabolism contribute to IR.Data on wild-type (wt, black bars and traces) and LowOXPHOS (orange bars and traces) mice are shown.
A–E (A, C) Plasma (A) and Skm (C) BCAA levels in wt and LowOXPHOS mice (wt, n = 4; LowOXPHOS, n = 4). (B, D, E). Scheme of the BCAA catabolism pathway (B, left panel)
and 14C(u)-leucine and 14C(u)-isoleucine uptake (B, right panels), oxidation (D) and incorporation into lipids (E) in myocytes expressing or not ATPIF1H49K. Bars are
the mean  SEM of n = 3 experiments, 6 replicas/condition.
F Longitudinal (left panels) and transversal (right panels) slices of soleus stained with hematoxylin/eosin. im-WAT infiltrations and fiber shrinkage (arrows) in HFD-
fed LowOXPHOS mice (wt + HFD, n = 4; LowOXPHOS + HFD, n = 4; 10 fields/mouse).
G–I Motor function tests. Rotarod (G; wt, n = 7; LowOXPHOS, n = 6), open field (H; wt, n = 4; LowOXPHOS, n = 4) and grip force (after fatigue, I; wt, n = 7; LowOXPHOS,
n = 6) tests. In (H), lines represent the movement of the mice in the cage. The histogram represents the relative time that wt and LowOXPHOS mice expended in the
corners.
J, K Quantitative Skm lipidomics at day 80 of HFD (J). The color scale (brown to blue) in the heat map represents LowOXPHOS/wt amounts of detailed lipid species. A P-
value ≤ 0.05 was considered statistically significant (red). In the lower heat map (K), the color scale (yellow to blue) highlights an increase in DAG in HFD-fed
LowOXPHOS mice. Each sample is a pool from 4 mouse extracts. Histograms show the total amounts of Skm DAG (wt, n = 8; LowOXPHOS, n = 8).
L Blood triglycerides on the 80th day of HFD (wt + HFD, n = 10; LowOXPHOS + HFD, n = 10).
M Skm relative expression of the GLUT1, GLUT3, PPARb/d and PGC1a by qPCR (wt, n = 5; LowOXPHOS, n = 5).
N qPCR relative expression of myokines (wt, n = 5; LowOXPHOS, n = 5). Red or blue color represents higher or lower % expression, respectively, compared to that in wt.
SPARC, osteonectin; OSTN, musclin; LIF, interleukin 6 family cytokine; FKN, fractalkine; FSTL1, follistatin-like protein 1; FNDC5, irisin; ADIPOQ, adiponectin.
O Blood glucose following the administration of HFD (wt + HFD, n = 10; LowOXPHOS + HFD, n = 10). T2D onset occurred on day 80 in wt and day 60 in LowOXPHOS
mice.
P Insulin (ITT) and glucose (GTT) tolerance tests on day 60 of HFD (wt + HFD, n = 10; LowOXPHOS + HFD, n = 10). LowOXPHOS but not wt mice appeared diabetic.
Data information: Bars are the mean  SEM of the indicated (n) mice/genotype *P < 0.05 when compared to wt by ANOVA or Student’s t-test. See also Figs EV3 and
EV4, and Table EV3.
8 of 24 The EMBO Journal 39: e103812 | 2020 ª 2020 The Authors










ª 2020 The Authors The EMBO Journal 39: e103812 | 2020 9 of 24
Cristina Sánchez-González et al The EMBO Journal
not carboxin prevented the ATPIF1-dependent ROS production
(Fig 5J), suggesting a specific role for SDHA in this event.
Building upon the observation that high levels of ROS may
impair the stability and activity of ETC complexes (Acin-Perez et al,
2008; Cogliati et al, 2013), we next tested the effect of ATPIF1H49K
on ETC complex superassembly (Fig 5K). Blue-native (BN) gels and
relative clear-native (CN) in-gel activities were performed on IMM
solubilized proteins from wt or LowOXPHOS hindlimb muscles
(Fig 5K). No significant alterations in functionality and supramolec-
ular organization of CII, CIII, and CIV of the ETC were observed
(Fig 5K), whereas consistent with previous reports (Santacatterina
et al, 2016), the presence of ATPIF1H49K increased the oligomeriza-
tion of CV (Fig 5K). Remarkably, in LowOXPHOS mice, a subassembly
of CI with no activity was observed (Fig 5K), suggesting an early
phase of ROS-mediated CI degradation (Guaras et al, 2016).
Edaravone increases mitochondrial function and FA b-oxidation
In order to identify an activator of mitochondrial function that may
restore Skm homeostasis, we tested the effect of 702 FDA-approved
drugs on O2 consumption in C2C12 myocytes using palmitate as a
substrate (Fig 6A). This approach identified 41 compounds with a
potential mitochondrial enhancer function, as defined by an
increased maximum respiration (Fig 6A and B).
Next, we analyzed the effect of the identified hits on 9,103H(N)-
palmitic acid oxidation in myocytes (Fig 6C), a readout of mitochon-
drial FFA b-oxidation. This analysis uncovered edaravone, a lipophilic
antioxidant drug currently used to recover from stroke in Japan and to
treat ALS in the US (Rothstein, 2017), as a potent activator of b-oxida-
tion (Fig 6D). Edaravone treatment exhibited the capacity to increase
basal, oligomycin-sensitive, and maximum mitochondrial respiration
(Fig 6E). Moreover, edaravone partially restored palmitate b-oxida-
tion flux inhibited by ATPIF1H49K4 in C2C12 (Fig 6F) and in primary
myocytes from LowOXPHOS mice (Fig 6G).
In vivo edaravone treatment restores ROS imbalance and
lipid metabolism
In order to understand whether the previously reported antioxidant
property of edaravone (Rothstein, 2017) is mitochondria-mediated,
we assayed its capacity of quenching mitochondrial ROS in
myocytes. Confirming the hypothesis, 3-h treatment with edaravone
or mitochondrial-specific antioxidant MitoQ but not N-acetyl-
cysteine (NAC) significantly reduced mitochondrial ROS production
(Fig 7A). To increase mitochondrial activity and reduce ROS in Skm
in vivo, we administered 3 mg/kg edaravone to wt and LowOXPHOS
littermates (Fig 7B–L). Consistent with its in vitro effect, a 1-month
edaravone administration reversed the ATPIF1H49K-dependent alter-
ations in the redox system (Fig 7B).
We next tested the effect of reverting the mitochondrial imbal-
ance observed in LowOXPHOS mice on hyperlipidemia and insulin
resistance. Indeed, mitochondrial ROS are known modulators of
lipogenesis through the Akt-PGC1a axis (Martinez-Reyes & Cuezva,
2014). Accordingly, edaravone and MitoQ but not NAC significantly
increased the myocyte expression of PGC1a and reduced the TNFa
production (Fig 7C). Consistently and in line with the observed
edaravone-mediated increase in lipid catabolism in vitro (Fig 6F and
G), the levels of the rate-limiting lipid synthesis enzymes ACLY and
FASN were downregulated in both wt and LowOXPHOS mice adminis-
tered edaravone (Fig 7D). Remarkably, in LowOXPHOS animals, a 1-
month edaravone treatment restored the levels and activity of mito-
chondrial OXPHOS complexes. Thus, ETFA, ETFB, and SDHA
protein expression was reduced to wt levels (Fig 7E). Similarly,
edaravone restored the physiological level of acetylation of SDHA
(CII) (Fig 7F) and abolished the ROS-mediated degradation of CI
(Fig 7G) observed in LowOXPHOS mice (Fig 5K). As a consequence of
these events, when mice were fed a HFD and simultaneously treated
with edaravone, no differences were observed in body weight
(Fig 7H), Skm whitening (Fig EV5E), or in v-WAT (Fig 7I) between
◀ Figure 4. The lipogenic switch alters the redox system and lipid-related OXPHOS components.Data on wild-type (wt, black bars) and LowOXPHOS (orange bars) mice are shown.
A v-WAT iTRAQ ratio of proteins from BCAA catabolism (wt, n = 4; LowOXPHOS, n = 4). Higher intensities of blue colors represent lower LowOXPHOS/wt expression
ratios.
B Odd chain FAs in Skm and WAT from wt (n = 8) or LowOXPHOS (n = 8) mice.
C, D Representative WB expression (C) and iTRAQ analysis (D) of v-WAT proteins from lipid metabolism. Each sample contains extracts from 3 mice. The histogram
shows the quantifications (wt, n = 6; LowOXPHOS, n = 6).
E v-WAT weight expressed as a percentage of the wt (wt, n = 12; LowOXPHOS, n = 12).
F Quantitative lipidomics in v-WAT. The color scale (brown to blue) in the heat map represents LowOXPHOS/wt amounts of specific lipid species. A P-value ≤ 0.05 was
considered statistically significant (red). Each sample is a pool from 4 mouse extracts, n = 8/genotype.
G v-WAT amounts of triacylglycerides (TAGs) and diacylglycerides (DAGs) (wt, n = 8; LowOXPHOS, n = 8).
H Higher saturated lipid species in LowOXPHOS mice compared to wt (wt, n = 8; LowOXPHOS, n = 8).
I MitoSox staining in myocytes expressing or not ATPIF1H49K. The right histogram shows the quantification of mitochondrial ROS. Bars are the mean  SEM of n = 3
experiments, 12 replicas/condition.
J Representative WB of Skm lipid peroxidation and redox system proteins. Two samples per condition are shown. Each sample contains extracts from 3 mice.
Histograms represent quantification (wt, n = 6; LowOXPHOS, n = 6). 4-Hydroxynonenal (4HN), peroxiredoxin 2, 3 and 6 (PRX), superoxide dismutase 1 and 2 (SOD),
catalase (CATA) and glutathione reductase (GSR) immunoblots are shown. bF1 is presented as a loading control.
K Representative WB of Skm OXPHOS and related system proteins. Two samples per condition are shown. Each sample contains extracts from 3 mice. Histograms
represent quantification (wt, n = 6; LowOXPHOS, n = 6). NDUFA9 (CI), SDHA and B (CII), ETF subunits A and B, ETFDH, CoreII (CIII), subunit 1 (CIV), bF1(CV) and
hATPIF1 immunoblots are shown. Tubulin is presented as a loading control. See also Fig EV5.
L Skm iTRAQ ratio of FADH2-binding proteins (wt, n = 12; LowOXPHOS, n = 12). A higher intensity of red color represents a higher LowOXPHOS/wt expression ratio.
M Oxidized FAD levels and the reduced/oxidized FAD ratio in Skm extracts (wt, n = 8; LowOXPHOS n = 8).
Data information: Bars are the mean  SEM of the indicated (n) mice/genotype. *P < 0.05 when compared to wt by Student’s t-test. See also Figs EV4 and EV5, and
Table EV3.
Source data are available online for this figure.
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LowOXPHOS and wt mice. Moreover, in LowOXPHOS mice a slight
reduction in plasma BCAA levels (Fig EV5F) and 14C(u)-BCCA
uptake (Fig EV5G) was observed compared to no-treated animals.
Despite edaravone did not significantly affect food intake
(Fig EV5H), at day 60 of HFD, when nontreated LowOXPHOS mice
were already prediabetic, edaravone-treated LowOXPHOS mice
showed similar insulin and glucose sensitivity to control mice
(Fig 7J). To note that edaravone delayed the onset of T2D in both
genotypes: Interestingly, at day 80 of HFD, when both nontreated
wt and LowOXPHOS mice were insulin-resistant (Fig 7K), GTT values
indicated that edaravone-treated animals were still insulin-sensitive
(Fig 7K) and developed T2D only at day 90–100 of HFD (Fig 7K and
L). Altogether, these in vivo studies identify edaravone as a drug
with therapeutic potential for the treatment of mitochondrial-
derived metabolic disorders.
Discussion
Increasing evidence has associated muscle mitochondrial dysfunc-
tion with metabolic syndrome, but whether the former is a cause or
a consequence of the latter remains controversial. To answer this
question, we generated the first mouse model of the interference of
mitochondrial activity in Skm by the expression of the human active
inhibitor of ATP synthase (Formentini et al, 2014; Boreikaite et al,
2019) in ACTA1-positive myocytes. These animals presented higher
fat deposits in both Skm and WAT, indicating perturbations in
whole-body lipid metabolism. In oxidative Skm, reciprocal cross-
talk between glucose and FA metabolism determines fuel selection
through the Randle cycle (Samuel & Shulman, 2016). Altered nutri-
ent utilization and metabolic rewiring upon defective mitochondrial
activity has been proposed with different pathway fluxes involved
(Gaude & Frezza, 2014; Liu et al, 2016; Gaude et al, 2018). Consis-
tent with this, in our model, impairment of OXPHOS triggers the
shift to a lipogenic phenotype of a highly oxidative nonlipogenic
tissue such as muscle (Fig 8). Indeed, upon ATP synthase inhibi-
tion, lipogenic enzymes are overexpressed and activated, and
acetyl-CoA accumulates in myofibers to fuel the rate of de novo lipid
synthesis. In physiological and normoxic conditions, glycolysis and
FFA b-oxidation represent the major sources of cellular acetyl-CoA
(Pietrocola et al, 2015). However, the contribution of these two
pathways to promoting lipogenesis in our model is unlikely due to
the phosphorylation-mediated inactivation of PDH that reroute the
glycolytic rate to lactate production (Patel et al, 2014) along with
the observed inhibition of FFA b-oxidation in LowOXPHOS mice. In
this regard, we suggest that a reduction in the FFA entrance into the
mitochondria (Foster, 2012; Formentini et al, 2017a) along with the
acetyl-CoA-mediated acetylation and inactivation of proteins
involved in b-oxidation (Pietrocola et al, 2015) may play a part in
the mechanism underlying the reduction in lipid catabolism upon
ATP synthase inhibition.
We are also tempted to exclude that the generated lactate was
transformed into glycerol-3-phosphate and utilized for lipid synthe-
sis. Despite PCK1, the master regulator of glyceroneogenesis
(Hanson & Hakimi, 2008), is highly overexpressed in Skm of
LowOXPHOS mice (Fig EV1), glyceroneogenesis is a minor pathway
in muscle, and the carbon14 atoms derived from labeled glucose
accumulate in lipids in a similar manner in control and ATPIF1H49K
expressing myocytes.
An alternative route for acetyl-CoA production is through utiliza-
tion of BCAAs (White & Newgard, 2019). This pathway shares with
b-oxidation many enzymes that are highly upregulated in our
proteomic dataset in LowOXPHOS mice. Interestingly, the ATP
synthase-mediated LD formation in myocytes is prevented by
removing BCAAs from culture media, what might suggest that upon
OXPHOS inhibition, BCAA oxidation participates in acetyl-coA
synthesis and increased lipogenesis. Supporting this hypothesis,
carbon14 leucine and isoleucine are highly oxidized to CO2 and
accumulated faster in myocyte lipid fraction when the ATP synthase
is inhibited. Consistently, it has been proposed that upon metabolic
stress, BCAA catabolism fuels lipogenesis (Green et al, 2016;
Wallace et al, 2018) and competes for lipid oxidation, causing the
accumulation of toxic lipid intermediates (White et al, 2016).
Insulin-resistant mice have been described to shift BCAA metabo-
lism from WAT and liver toward muscle, increasing the Skm rate of
BCAA oxidation (Neinast et al, 2019), what is observed in our
◀ Figure 5. Hindering the ATP synthase activity feeds back to OXPHOS dysfunction by inhibiting CII and generating a SDHA-dependent burst in ROS.A Enzymatic activity of respiratory complex CII in Skm isolated mitochondria from wt and LowOXPHOS mice fed with chow or HFD (wt, n = 4; LowOXPHOS, n = 4;
wt + HFD, n = 4; LowOXPHOS + HFD, n = 4).
B Polarographic profiles of isolated mitochondria from wt (lower trace) and LowOXPHOS (upper trace) animals using succinate (left graph) or palmitoyl-carnitine (right
graph) as a substrate. Quantification of maximal respiration in the right histogram. Bars are the mean  SEM of n = 3 mice/genotype, 3 traces/mouse; OL,
oligomycin; Ant A, antimycin A.
C–E 2D-PAGE of Skm extracts (C, D) and acetylated proteins (E) from wt (n = 4) and LowOXPHOS (n = 3) mice. The isoelectric point (pI) of the CII subunits SDHB (C) and
SDHA (D) was calculated by protein migration in pH 3–10 NL strips.
F Immunocapture (IP) of SDHA blotted with anti-acetyl-K antibody (upper panel) and of acetylated proteins blotted with anti-SDHA antibody (middle panel) in Skm
isolated mitochondria from wt (n = 3) and LowOXPHOS (n = 3) mice.
G, H PyMOL cartoon representations of acetylated lysines in SDHA related to CII activity. Six acetylated-K are shown.
I MitoSox staining in myocytes expressing or not ATPIF1H49K. The left scheme illustrates where each ETC inhibitor works. The right histogram shows the
quantification of mitochondrial ROS. Bars are the mean  SEM of n = 3 experiments, 12 replicas/condition.
J MitoSox staining in myocytes expressing or not ATPIF1H49K. The left scheme illustrates where each CII inhibitor works. The right histogram shows the
quantification of mitochondrial ROS. Bars are the mean  SEM of n = 3 experiments, 12 replicas/condition.
K Representative blue-native immunoblots (BN) and clear-native in-gel activity (CN) of Skm mitochondrial membrane proteins from wt (n = 3) and LowOXPHOS
(n = 3) 2-month-old mice. The migration of the respiratory complexes/supercomplexes CIV is indicated. Subassembly of CI (with no activity, suggesting
degradation) was observed in LowOXPHOS mice. VDAC is shown as a loading control.
Data information: *,#P < 0.05 when compared to wt or LowOXPHOS, respectively, by ANOVA and Student’s t-test. See also Fig EV5.
Source data are available online for this figure.
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model. This also results in faster lipid transport across the
membranes favoring higher FFA blood levels and lipotoxicity (Jang
et al, 2016). Accordingly, acyl-glyceride species accumulated in the
myofibers and blood of LowOXPHOS mice, which caused these
animals to develop T2D faster than control animals. Indeed, the
application of metabolomics technologies has revealed that BCAA
fluxes and related metabolites are more strongly associated with
homeostatic model assessment of insulin resistance (HOMA-IR)
than many common lipid species (Newgard, 2012). Remarkably,
metformin, the first-line medication for the treatment of T2D and
known OXPHOS modulator, has been shown to significantly dimin-
ish BCAA oxidation (Liu et al, 2016).
We cannot exclude the contribution of another minor pathway to
the observed lipogenesis because acetyl-CoA could be partially
derived from the rewiring of glutamine metabolism through reduc-
tive carboxylation (Mullen et al, 2011). This is a form of rewired
TCA cycle that in Skm may occur under specific metabolic stresses,
such as hypoxia (Metallo et al, 2011) or mtDNA mutations (Chen
et al, 2018; Gaude et al, 2018), and produces acetyl-coA from gluta-
mine, prompting the anaplerotic reactions that increase metabolite
levels for lipid synthesis. Interestingly, iTRAQ analysis revealed an
upregulation of the key regulators of reductive carboxylation IDH
(Metallo et al, 2011) and MDH (Gaude et al, 2018) in Skm from
LowOXPHOS compared to levels in wt mice.
Although the implication of BCAA metabolism and reductive
carboxylation in the setting of IR is still object of debate, the connec-
tion between the ectopic accumulation of lipids and impaired
glycemic control has been widely documented (Despres & Lemieux,
2006). Both ceramide and DAG accumulation have been reported in
Skm and liver from T2D subjects (Szendroedi et al, 2014), as well
as a direct connection between lipotoxicity and IR (Jornayvaz &
Shulman, 2012; Turpin-Nolan et al, 2019). Specifically, DAG species
containing C16:0, C18:0, C18:1, C18:2, or C20:4 FA showed the
strongest relationship with IR in obese and T2D individuals
(Szendroedi et al, 2014). Interestingly, changes in these species
have been detected in our model (Figs 3K, and EV4D and E).
However, a muscle-specific phosphoethanolamine cytidylyltrans-
ferase knockout mouse, displaying a 200% increase in Skm accumu-
lation of DAGs but normal mitochondrial b-oxidation activity, failed
to display impaired insulin sensitivity and presented unexpectedly
enhanced exercise performance (Selathurai et al, 2015). This could
be related to the capacity of b-oxidation to remove fat from muscles,
circumventing ectopic lipid accumulation, and resulting in increased
energy production. Accordingly, we suggest that neither
mitochondrial dysfunction nor perturbations in lipid species per se
are determinants for the pathological setting, pointing to the neces-
sary combination of the two events for IR. Supporting this hypothe-
sis, a modification of the hepatic sphingolipid pattern that finally
results in the impairment in mitochondrial homeostasis has been
recently demonstrated to reduce insulin sensitivity (Hammerschmidt
et al, 2019). Interestingly, similar results are observed in our
complementary model, where mitochondrial activity inhibition trig-
gers an alteration in the abundance of several lipid species, includ-
ing ceramides, DAGs, and TAGs.
TAG synthesis in particular has been recently linked to mito-
chondrial activity (Benador et al, 2018). The cross-talk between
lipid storage and mitochondria in fat-oxidizing tissues such as
brown adipose tissue (BAT) has been described to facilitate acyl-
glyceride production and lipid vesicle expansion (Benador et al,
2018, 2019). In line with this, we report that Skm intrafiber forma-
tion of LDs occurred in an ATP synthase-dependent manner, which
may explain the observed burst in lipid production and storage upon
OXPHOS inhibition. Accordingly, liver-specific ablation of MFN-2,
which triggers defective mitochondrial fusion, modified PS transfer
and phospholipid synthesis, and leads to the development of NASH-
like hyperlipidemia (Hernandez-Alvarez et al, 2019). Therefore,
herein we support the idea that mitochondrial OXPHOS is crucial in
maintaining lipid and glucose homeostasis.
Mechanistically, we propose that the ATP synthase-dependent
dysregulation of Skm lipids further promotes a dysfunctional ETC
that results in boosting ROS production. Upon the increase in lipoge-
nesis, the switch from NADH to FADH2 leads to a greater proportion
of electrons being transferred to CII or other FAD-dependent dehy-
drogenases rather than to CI. When FADH2 is used as a substrate for
mitochondrial respiration, O2 consumption increases to maintain
membrane potential (Hinkle, 2005) and favors the so-called
reversed electron transfer (Scialo et al, 2016). Under these condi-
tions, superoxide production is enhanced (Robb et al, 2018), which
contributes to CI degradation (Guaras et al, 2016). In our model, the
acetylation-mediated partial inhibition (Finley et al, 2011) of the
respiratory CII catalytic subunit SDHA, along with the overexpres-
sion of FADH2-producing enzymes, triggers the accumulation of
FADH2 in myocytes.
Inhibiting the activity of ATP synthase is known to stimulate the
production of ROS (Balaban et al, 2005; Martinez-Reyes & Cuezva,
2014). This mild ROS signal is not detrimental in terms of cell death
and rather seems to participate in an ATP synthase-mediated signal
transduction to the nucleus (Formentini et al, 2012). However, no
◀ Figure 6. Edaravone as a mitochondrial metabolism enhancer.A, B The schematic illustrates the screening process of 702 drugs related to the mitochondrial respiratory capacity assessed by Seahorse XFe96 in C2C12 myocytes.
Palmitate is used as a substrate. A total of 41 hits were identified. Maximum respiration (Max R, % of untreated cells) of compounds categorized by their
therapeutic use (B).
C, D The schematic illustrates the screening process of the 41 hits on FFA b-oxidation using 9,103H(N) palmitic acid as a substrate in C2C12 myocytes. Ten enhancers
were identified. (D) Correlation between the maximum respiration (x) and palmitate b-oxidation (y). Colors identify classes of pharmaceuticals as in (B). Edaravone
was selected as a hit.
E Representative respiratory profile of C2C12 myocytes treated (green trace) or not treated (black trace) with 2 lM edaravone. The CPT1 inhibitor etomoxir was used
as a negative control. OCR, oxygen consumption rate; OL, oligomycin; DNP, 2,4-dinitrophenol; Rot, rotenone; Ant A, antimycin A. Quantification in right histogram.
Bars are the mean  SEM of 12 replicas/condition.
F, G FFA b-oxidation in C2C12 myocytes transfected with CRL or ATPIF1H49K plasmids (F) and in primary myotubes from wt and LowOXPHOS mice (G), treated (green bars)
or not with 2 lM edaravone. Bars are the mean  SEM of n = 3 experiments, 9 replicas/condition.
Data information: (E–G) *P < 0.05 when compared to wt by ANOVA and Student’s t-test.
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sites for ROS production have been described inside the ATP
synthase structure (Zhao et al, 2019). We herein demonstrated that
the acetylation and inhibition of SDHA is causal in the ATP
synthase-mediated boost in ROS, which finally triggers a metabolic
response in mice that affects IR. In order to support this, we provide
evidence that edaravone supplementation, which induced a ROS-
mediated repression of lipogenesis, reestablished lipid homeostasis
and insulin sensitivity (Fig 8). Although the antioxidant property of
edaravone is known (Rothstein, 2017), the exact mechanism of
action for this drug is unknown. Herein, we unveiled its effect on
◀ Figure 7. In vivo edaravone treatment rewires the ROS-driven lipogenic switch and prevents IR.Data on wild-type (wt, black bars and traces) and LowOXPHOS (orange bars and traces) mice treated or not with 3 mg/kg edaravone are shown.
A Mitochondrial ROS after 3 h treatment with 2 lM edaravone (green bars), 10 nM MitoQ (purple bars) or 1 mM NAC (blue bars). Bars are the mean  SEM of n = 3
experiments, 9 replicas/condition.
B Representative WB expression of Skm ROS system proteins in mice administered (30 days) edaravone. Two samples per condition are shown. Each sample contains
extracts from 3 mice (wt + edaravone, n = 6; LowOXPHOS + edaravone n = 6). Peroxiredoxin 2 and 3 (PRX), catalase (CATA) and glutathione reductase (GSR)
immunoblots are shown. GAPDH is presented as a loading control.
C qPCR relative expression of TNFa and PGC1a in myocytes treated for 24 h with 2 lM edaravone (green bars), 10 nM MitoQ (purple bars) or 1 mM NAC (blue bars).
Six replicas/condition.
D, E Representative WB expression of Skm de novo lipid synthesis (D) and OXPHOS (E) proteins. One month of edaravone treatment downregulated FASN and ACLY in
both wt and LowOXPHOS mice (D) and rewired the upregulation of ETF-A, ETF-B and SDHA proteins to the levels of wt (E). Two samples per condition are shown.
Each sample contains extracts from 3 mice. Tubulin or bF1 is presented as a loading control. Quantifications in lateral histograms (wt, n = 6; LowOXPHOS, n = 6;
wt + edaravone, n = 6; LowOXPHOS + edaravone, n = 6).
F 2D-PAGE of Skm extracts from wt (n = 3) and LowOXPHOS (n = 3) mice treated with edaravone. The pI of SDHA, calculated by protein migration in pH 3-10 NL strips,
was the same for both genotypes.
G Representative blue-native immunoblots (BN) of Skm mitochondrial membrane proteins from 2-month-old mice treated with edaravone for 30 days
(wt + edaravone, n = 3; LowOXPHOS + edaravone, n = 3). The migration of the respiratory complexes/supercomplexes CI-CIV and hATPIF1 is indicated. VDAC is
shown as a loading control.
H Mouse body weight following the administration of HFD and edaravone.
I v-WAT amounts at day 60th of HFD in mice treated with edaravone.
J Insulin (ITT) and glucose (GTT) tolerance tests after 60 days of HFD in mice treated with edaravone.
K GTT after 80 days of HFD (left) and ITT after 90 days of HFD (right) in wt and LowOXPHOS mice treated with edaravone, showing that the compound has an
improving effect itself.
L Blood glucose following the administration of HFD. T2D onset occurred on day 90 in wt and LowOXPHOS mice treated with edaravone.
Data information: H–L: wt + HFD, n = 5; LowOXPHOS + HFD n = 4; wt + HFD + edaravone, n = 10; LowOXPHOS + HFD + edaravone n = 9. Bars are the mean  SEM of
the indicated (n) mice/genotype. *P < 0.05 when compared to wt by ANOVA and Student’s t-test. See also Fig EV5.
Source data are available online for this figure.
Figure 8. The OXPHOS-mediated lipogenic reprogramming is prevented by edaravone.
The schematic illustrates the effect of in vivo edaravone administration in Skm from LowOXPHOS mice. Restraining OXPHOS generates a ROS-mediated rewiring of lipid
metabolism through enhanced BCAA catabolism and lipid synthesis. Skm and WAT perturbations in lipid species are observed, defining a LowOXPHOS phenotype of adiposity
and lipotoxicity. Edaravone treatment restores normal ROS and lipid metabolism, reducing v-WAT deposits and preventing the setting of IR mediated by mitochondrial
dysfunction.
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targeting mitochondria, inhibiting superoxide production and induc-
ing a hypolipidemic rewiring of mitochondrial lipid metabolism to
an increase FA catabolism.
Altogether, this study provides a mechanistic explanation for the
link between mitochondrial dysfunction and the onset of metabolic
disorders. The clinical relevance of our preclinical findings should
be validated before application to human health. Nevertheless, our
data suggest edaravone as a potential drug of interest for a novel
approach in mitochondrial-derived metabolic disorders. Further-
more, the fact that edaravone is a FDA-approved molecule may
guarantee a rapid translation into clinical applications.
Materials and Methods
Reagents
The 11,018 FDA-Approved Library (Selleckchem) was used; C2C12
(ATCC©) or primary myocytes were incubated for 3 h with 702
compounds from the library at a final concentration of 2 lM. Edar-
avone was purchased from Selleckchem and used at 2 lM (in vitro)
or injected i.p. at 3 mg/kg (in vivo). MitoQ was kindly gifted by
Professor Michel P. Murphy. A comprehensive list of reagents and
antibodies utilized is detailed in Table EV1.
Animal studies
All animal experimentation procedures were performed after the
approval of the Institutional Review Board (Ethical Committee of
the UAM University and Madrid Community, Spain; CEI-24-571,
PROEX 183/17) in compliance with animal policies and ethical
guidelines of the “European Guidelines for the Care and Use of
Laboratory Animals” (EU Directive 86/609). All procedures follow
the ARRIVE guidelines.
For the in vivo studies, B6;C3-Tg(ACTA1-rtTA,tetO-cre)102MonK/
J mice (ATPIF1H49K|
T) were purchased from The Jackson Laborato-
ries. The Tet-on double transgenic ATPIF1H49K|
T/H mouse was
obtained by breeding ATPIF1H49K|
T with the ATPIF1H49K|
H mouse
(Formentini et al, 2014), which integrates in its genome the
ATPIF1H49K-TRE construct under a tetracycline-regulated promoter.
Mice were maintained on the (C57BL/6 × C3H)F2 background.
Administration of 2 mg/ml doxycycline in the drinking water for at
least 2 weeks was used to turn on the Skm expression of ATPIF1H49K
protein. All experiments were performed on age-matched male
littermate wt and ATPIF1H49K|
T/H mice. In order to minimize the
number of animals, we used power analysis to calculate the minimum
sample size using the free software DOEUMH (https://samplesize
umh.shinyapps.io/DOEUMH) based on the TrialSize library of the R
program (R Core Team). We selected the procedure KMeans—
ANOVA, fixing the significance to 0.05, power to 0.08, and a drop-out
of 5%. We took into consideration differences between averages of
about 1.5, as for omic studies. Minimum number of mice/group is 12
mice/group. Mouse motor function was evaluated by rotarod, grip
force/strength, and open field tests. Details are shown in the
Expanded View Section. All tests were performed in a blinded fashion.
Randomization was assessed by equally distributing experimental
groups across multiple cages and balancing the location of the mouse
cages on the racks.
T2D onset and monitoring: glucose and insulin tolerance tests
Eight-week-old male animals were fed ad libitum either a standard
or a HFD diet (Research Diets) for 14 weeks. To monitor the onset
of T2D, blood glucose and body weight were measured once and
twice a week, respectively. Glucose and insulin tolerance tests (GTT
and ITT) were performed by injecting glucose (0.2 g/mg) or insulin
(0.8 UI/kg) after 12 or 4 h of starvation, respectively. The blood
glucose concentration was measured using One Touch Select Plus
strips (Johnson & Johnson) and a measurement apparatus.
Primary cultures of myotubes
Primary Skm cell cultures (myotubes) were established from
hindlimb muscle biopsies from wt or ATPIF1H49K|
T/H mice
(Formentini et al, 2017a). Cells were propagated in SkGM media
(Lonza) and supplemented with the accompanying bullet kit but
omitting insulin. At 80–90% confluence, cells were differentiated in
a-MEM containing 2% FBS and 100 nM insulin. C2C12 mouse
myoblasts were cultured in DMEM 10% FBS, 1 mM glutamine, and
amino acids. At 80–90% confluence, cells were differentiated in
DMEM containing 2% FBS and 100 nM insulin.
Cell transfection
At ~ 70% confluence, myoblasts were transfected with CRL or
ATPIF1H49K plasmid (Formentini et al, 2017a) (pCMV-SPORT6-
ATPIF1H49K or pCMV-SPORT6-control) using Lipofectamine 2000
transfection reagent. Experiments were performed 24 h post-
transfection.
Skeletal muscle mitochondria
Fresh hindlimb muscles from wt and ATPIF1H49K|
T/H mice were
minced and homogenized in a glass–glass homogenizer in buffer A
(320 mM sucrose, 1 mM EDTA, and 10 mM Tris–HCl, pH 7.4). Skm
mitochondria were obtained by centrifugation as previously
described (Formentini et al, 2017a). Briefly, unbroken cells and
tissue were removed by centrifugation at 1,000 g for 5 min at 4°C;
mitochondria were obtained by supernatant centrifugation at
11,000 g for 15 min at 4°C.
Oxygen consumption rates
The oxygen consumption rate (OCR) in isolated mitochondria (200 lg
protein) was determined with a Clark-type electrode. Glutamate/malate
(10 mM), succinate (10 mM), or malate (2 mM) plus palmitoyl-
carnitine (0.05 mM) was used as respiratory substrates in the presence
or absence of 0.5 mM ADP, 5 lM oligomycin (OL), 5 lM FCCP, and
1 lM antimycin A (Ant A). The composition of the respiration buffer is
225 mM sucrose, 5 mM MgCl2, 10 mM KCl, 10 mM phosphate buffer,
1 mM EGTA, 0.05% BSA, and 10 mM Tris–HCl, pH 7.4.
The OCR in myotubes and C2C12 cells treated with the drug
library was determined in an XF96 Extracellular Flux Analyzer with
the XFe96 Flux Pack following the manufacturer’s protocols. Cells
were starved for 12 h in low-glucose DMEM (0.05 mM glucose, 1%
FBS) and then changed to KHB media (111 mM NaCl, 4.7 mM KCl,
1.25 mM glutamine, 5 mM HEPES, pH 7.4). BSA-conjugated
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palmitate (1 mM sodium palmitate, 0.17 mM BSA solution) was
added as the main substrate. The final concentration and order of
injected substances was 3 lM OL, 0.25 mM DNP, 1 lM rotenone,
and 1 lM antimycin A. When indicated, 1 mM carnitine, 10 nM
etomoxir, or 2 lM of FDA-approved library compounds were added.
Compounds that positively affected respiration by a factor of at least
30% were selected for further screenings.
Determination of mitochondrial enzyme activities
Isolated mitochondria were used for the spectrophotometric deter-
mination of respiratory complexes I and II, according to Barrien-
tos et al (2009) with minor modifications. Complex I activity was
measured at A340 using 100 lg of mitochondria. Mitochondria
were resuspended in 1 ml of CI/CII buffer (25 mM K2HPO4,
5 mM MgCl2, 3 mM KCN, and 2.5 mg/ml bovine serum albumin)
containing 0.1 mM UQ1, 0.1 M NADH, and 1 mg/ml antimycin A.
Inhibition of the activity was accomplished by the addition of
1 lM rotenone. Complex II activity was measured at A600 using
100 lg of mitochondria. Mitochondria were resuspended in 1 ml
of CI/CII buffer containing 30 lM DCPIP, 1 lM rotenone, 1 lM
antimycin A, 10 mM succinate, and 6 mM phenazine
methosulfate.
Mitochondrial ROS
The mitochondrial production of superoxide in myocytes was moni-
tored by flow cytometry using 5 lM MitoSoX (Formentini et al,
2012). Cells were analyzed in a BD FACScan. Where indicated, ETC
inhibitors were added at following concentrations: 1 lM rotenone,
100 lM malonate, 10 or 100 lM carboxin, 1 lM antimycin A.
FAD, ATP, NADP, BCAA, lactate, FFA, free glycerol, and
acetyl-CoA determinations
Metabolites were measured in 40 mg of hindlimb muscle or adipose
tissue from wt and ATPIF1H49K|
T/H mice using a FLUOstar-Omega
spectrophotometer (BMG LABTECH).
Tissue was homogenized in 1 M perchloric acid, and the
oxidized FAD content was measured colorimetrically in neutral-
ized samples using the FAD Assay Kit (Abcam) at A570. Phena-
zine methosulfate was used on neutralized samples to transform
free FADH and FADH2 into FAD and measure the total pool of
FAD + FADH + FADH2. The ATP concentration in muscle was
determined using the ATP Bioluminescence Assay Kit CLS II
(Roche). NADP/NADPH Quantification Kit (Sigma-Aldrich) and
PicoProbe Acetyl-CoA Fluorometric Assay Kit (BioVision) were
assessed following the manufacturer’s instructions. Absorbance
was read at 450 nm, and fluorescence at ex/em = 540/590. BCAA
levels in plasma or Skm tissue were measured using the Branched
Chain Amino Acid Assay Kit (Abcam). The initial rate of lactate
production was measured as previously described (Formentini
et al, 2012).
For FFA and free glycerol determination, tissues were homoge-
nized in 1 ml of 2-isopropanol in a TissueLyser (Qiagen). Five
microliters of Skm/WAT extracts or 5 ll of mouse blood serum was
used for FFA quantification using the Glycerol Quantification Kit
(Sigma-Aldrich) at A540. Quantification of specific lipid species was
assessed by lipidomics (see below). All results were adjusted for
exact protein contents.
FFA b-oxidation
Four days after differentiation, primary myotubes derived from wt
or ATPIF1H49K|
T/H mice or transfected C2C12 cells were incubated in
serum-free a-MEM containing [9,10-3H(N)] palmitic acid (Perkin
Elmer, 0.2 lCi, final concentration = 20 lmol/l). After incubation,
100 ll of the culture medium was placed over an ion-exchange
resin, and the Poly-Prep Chromatography column was washed with
water. Intact FFAs (charged state) were retained by the resin,
whereas the oxidized portion passed freely (Formentini et al,
2017a). The oxidized portion was measured in a scintillation coun-
ter with Ultima Gold LLT scintillation fluid (Perkin Elmer). All
results were adjusted for total cellular protein content.
14C(u)-leucine, 14C(u)-isoleucine, and 14C(u)-glucose uptake
and catabolism
For the measurement of substrate uptake, lipid synthesis, and CO2
production, myocytes were incubated in HBSS containing 0.3 mM
L-leucine, 0.3 mM L-isoleucine, or 5 mM d-glucose + 2 lCi/ml of
labeled 14C(u)-L-leucine, 14C(u)-L-isoleucine, or 14C(u)-D-glucose
(Perkin Elmer).
Uptake was measured as radioactivity incorporated in myocytes
after 0, 1, 2, 3, 5, or 10 min. Lipid fractions were separated by a
standard CHCl3/MeOH extraction at 0, 2, and 4 h. For CO2 produc-
tion, incubation was carried out in flasks in the presence of a paper
filter imbibed in 0.2 M KOH/NaOH solution. The C14-uptake and
C14-incorporation into lipids or CO2 were measured in a scintillation
counter with Ultima Gold LLT scintillation fluid (Perkin Elmer).
Quantitative lipidomics
Lipidomics was performed by Lipotype (https://www.lipotype.com/),
Max Planck Institute of Molecular Cell Biology and Genetics in Dres-
den, Germany. Details on methods are detailed in the Expanded View
Section.
Real-time PCR
We measured the Skm expression levels of: osteonectin (SPARC);
musclin (OSTN); LIF; fractalkine (FKN/CX3CL1); follistatin-like
protein (FSTL1); TNFa; IL15; IL6; PPARd; irisin (FNDC5); GLUT1;
GLUT3 and PGC1a. RNA was purified using 100 mg of hindlimb
muscles from 3 ATPIF1H49K and 3 wt mice following standard meth-
ods detailed in Expanded View Methods.
1D- and 2D-PAGE
Skm, WAT, brain and liver samples were freeze-clamped in liquid
nitrogen. Tissue proteins were extracted in a buffer containing
50 mM Tris–HCl, pH 8.0, 1% NaCl, 1% Triton X-100, 1 mM DTT,
0.1% SDS, and 0.4 mM EDTA, supplemented with protease and
phosphatase inhibitor cocktails. Lysates were clarified by centrifuga-
tion at 13,000 g for 15 min at 4°C. The resulting supernatants were
fractionated by SDS–PAGE and transferred onto PVDF or
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nitrocellulose membranes for immunoblot analysis. Blocking was
performed with 5% nonfat dried milk in Tris-buffered saline with
1% Tween 20 (TBST) or TBST supplemented with 5% BSA. The
primary monoclonal antibodies developed in our laboratory and
used in this study were anti-b-F1-ATPase (1:20,000), anti-HSP60
(1:10,000), and anti-GAPDH (1:20,000) (Formentini et al, 2014).
The antibodies specifically recognizing the human and mouse
ATPIF1 proteins were used at a 1:200 dilution (Formentini et al,
2017b). Other antibodies used are listed in Table EV1. Blots were
revealed using the Novex ECL HRP Chemiluminescent reagent,
and the intensity of the bands was quantified using a Bio-Rad GS-
900 densitometer and ImageJ 1.51v analysis software.
Isoelectric focusing (IEF) was performed with 13-cm Immobiline
DryStrips of 3–10 NL [not linear] pH gradient using an Ettan
IPGPhor3 IEF unit (GE Healthcare). In brief, 200 lg of fresh-frozen
Skm protein diluted in 250 ll of rehydration buffer (DeStreak Rehy-
dration Solution, GE Healthcare) containing 0.5% of the correspond-
ing IPG buffer (GE Healthcare) was loaded on the 13-cm strips. The
equilibrated strips were transferred to the top of a 9% SDS–
polyacrylamide gel. Electrophoresis was carried out using a Protean
II XI system (Bio-Rad) with constant current (30 mA/gel) at 4°C for
3 h. Western blot analysis of the fractionated proteins was
performed as described above.
Immunoprecipitation assays
Respiratory Complex II subunit SDHA and acetylated proteins
were immunocaptured from isolated mitochondria of Skm solubi-
lized with 1% n-dodecyl-b-D-maltoside (DDM). Protein from cell
lysates (400 mg) was incubated with 12 lg of the indicated
antibody (SDHA or acetyl-k) bound to EZ View Red Protein G
Affinity Gel (Sigma-Aldrich) at 4°C overnight. The beads were
washed twice before proteins were eluted and fractionated on
SDS–PAGE.
Blue-native (BN) and clear-native (CN) PAGE
For BN PAGE, Skm isolated mitochondria from wt and ATPIF1H49K|
T/H
mice were suspended in 50 mM Tris–HCl, pH 7.0, containing 1 M 6-
aminohexanoic acid at a final concentration of 10 mg/ml. The
membranes were solubilized by the addition of 10% digitonin (4:1
digitonin/mitochondrial protein). Next, 5% Serva Blue G dye in 1 M
6-aminohexanoic acid was added to the solubilized membranes. In
the CN-loading buffer, the Serva Blue G dye was replaced by 0.1%
Ponceau Red and 5.5% glycerol. In both BN and CN Native PAGETM,
Novex 3–12% Bis-Tris Protein Gels were loaded with 70 lg of
mitochondrial protein. The electrophoresis was performed at a
constant voltage of 70 V for 15 min, followed by 1 h at a
constant amperage of 10 mA. BN cathode buffer: Tricine 50 mM,
Bis-Tris 15 mM, pH = 7.0, Serva blue G 0.02%; BN anode buffer:
Bis-Tris 50 mM, pH 7.0; CN-cathode buffer: 50 mM tricine,
15 mM Bis-Tris, 0.05% sodium deoxycholate, pH 7.0, CN-anode
buffer: 50 mM Bis-Tris, pH 7.0.
In-gel mitochondrial ETC complex activities
CN PAGE gels containing solubilized mitochondria from wt and
ATPIF1H49K|
T/H mice were incubated with the following solutions
for assessing the specific ETC complex activities: Complex I: 5 mM
Tris–HCl, pH 7.4, 1 NTB tablet (5 mg; NitroBlue Tetrazolium
Tablet), and 10 mg/ml NADH; Complex II: 5 mM Tris–HCl, pH 7.4,
1 NTB tablet (5 mg), 10 mM sodium succinate, and 250 mM
phenazine methosulfate; Complex III: 50 mM phosphate buffer
(NaH2PO4 + NaHPO4, pH = 7.2) and 5 mg DAB; Complex IV:
50 mM phosphate buffer (NaH2PO4 + NaHPO4, pH = 7.2), 5 mg
DAB, and 5 mM reduced cytochrome C.
Quantitative proteomics (iTRAQ)
Isobaric tag for relative and absolute quantitation (iTRAQ) analysis
was carried out in the CBMSO Protein Chemistry Facility (Pro-
teoRed, PRB3-ISCIII and UAM University, Spain), following standard
protocols detailed in the Expanded View Section.
Electron microscopy
Sample preparation was performed by the Electron Microscopy
Facility at the CBMSO, UAM University, Spain. Skm tissue was fixed
with 4% paraformaldehyde and 2% glutaraldehyde in 0.1 M phos-
phate buffer. It was then treated with 1% osmium tetroxide in water
at 4°C for 1 h, dehydrated with ethanol, and embedded in TAAB
812 epoxy resin. Ultrathin 80-nm sections of the embedded tissue
were obtained using an ultramicrotome Ultracut E (Leica) and
mounted on carbon-coated copper 75-mesh grids. The sections were
stained with uranyl acetate and lead citrate and examined at 80 kV
in a JEOL JEM 1010 electron microscope. Images were recorded
with a TemCam F416 (4k × 4K) digital camera from TVIPS.
Immunofluorescence, confocal and optic microscopy
Hindlimb Skm from wt and ATPIF1H49K|
T/H mice was sliced, histo-
logically prepared, and stained with hematoxylin/eosin by the
Histology Facility at CNB-CSIC, UAM University, Spain. Deparaffi-
nation was performed at 60°C for 1 h, followed by hydration
(xylene, EtOH 100%, EtOH 90%, EtOH 70% and distilled H2O).
C2C12 cells were fixed in 4% PFA. Blockage was performed with 3%
goat serum in TBS 1× and 0.5% Triton X-100 at RT for 1 h. Dyes
were incubated in 1% goat serum in TBS 1× and 0.5% Triton X-100.
Stainings were as follows: ATPIF1 (1:500), b-F1-ATPase (1:10,000),
BODIPY 493/503 (2 lM) for LD; DAPI (1:1,000) for nuclei; and Oil
Red O (0.5%) for lipid staining. Complex I activity in slices was
performed as indicated for the CN in-gel activity. Images were
acquired on a Leica DMRE light microscope or by confocal micro-
scopy using a Bio-Rad Radiance 2000 Zeiss Axiovert S100TV.
ImageJ 1.51v software was used for quantification and image
analysis.
Statistical analyses
Statistical analyses were performed using a two-tailed Student’s
t-test. ANOVA and the Tukey’s post hoc test were used for multiple
comparisons, employing SPSS 17.0 and GraphPad Prism7 software
packages. Bonferroni correction was applied to avoid multiple
comparison errors. The results shown are the means  SEM.
P < 0.05 was considered statistically significant. The n used in each
statistical test is indicated in the figure legends.
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After normalization and filtering steps, proteomic and lipi-
domic data were analyzed by Gene Set Enrichment Analysis and
visualized by heat map and enrichment map using GSEA v3.0
and Cytoscape v3.6.1 free software. For details on the GSEA
parameter usage, see the GSEA web site (http://www.gsea-
msigdb.org/gsea/index.jsp). For bioinformatic studies, the PyMOL
Molecular Graphics System, Version 2.1.0 Schrödinger, LLC was
used. Real-time PCR analysis was assessed using 7500 Real-Time
PCR SDS 2.4 software.
Assessment of mouse motor function
Grip force/strength test
The grip force test was used to measure the maximum strength that
could be performed by a mouse with its forelimbs by taking advan-
tage of the animal’s tendency to grasp to surfaces. One mouse at a
time was left to grasp the metallic bars and then was gently pulled
away until its grasp is broken. The pulling was performed at
constant speed and sufficiently slow to permit the mouse to build
up a resistance against it. The test was repeated five times per
mouse, with at least 1 min elapsing between each of the five deter-
minations per animal.
Rotarod test
The rotarod test was performed in 3 days. Days 1 and 2 the mice
were trained, and the third day the test was performed. In day 1,
training consisted in 15 min at 13 rpms, and they were replaced in
the rod if they fell off. After 30 min of test ,mice were replaced on
the rod at run speeds ramping from 13 to 20 rpms for 15 min. In
day 2, training consisted in run speed from 13 to 20 rpms for
15 min and the second run was ramping from 13 to 20 rpms in
180 s for 15 min. The test involved run speed ramping from 13 to
20 rpms in 180 s and then let the animals in the rod until they fell
off. Their latency was measured. Mice that fell off four times within
60 s were discarded from the experiment.
Open field test
Mice were left free to explore an open field arena (40 × 40 cm) for
10 min, and activity was recorded for analysis with ANY-maze soft-
ware. To further explore fine alterations several aspects of the motor
activity were scored: speed (mean and maximum), time mobile (ex-
pressed as percentage of the total time of the trial). Layout: open
field area was virtually dissected in the following areas: center (in-
ner square), outer region (everything but the center square), and
corners (four triangular regions in the corners). Activity measure-
ments were evaluated in each region as well as the entire arena.
Abnormal phenotypes including thigmotaxis and anxiety-like behav-
ior are studied by virtual dissection of the arena with focus on the
corners and inner zone.
Real-time PCR
RNA was purified using 100 mg of hindlimb muscles from 3
ATPIF1H49K and 3 wt mice following a standard TRIzol/chloro-
form method. Purified RNA (1 µg) was retrotranscribed into
cDNA with the High-Capacity cDNA Reverse Transcription Kit.
Real-time PCR was performed using the Fast SYBR Master Mix
and ABI Prism 7900HT sequence detection system at the
Genomics and Massive Sequencing Facility (CBMSO–UAM). The
primers used to amplify the target genes are detailed in
Table EV2. Actin and GAPDH were selected as housekeeping
genes to normalize the mRNA levels. Standard curves with serial
dilutions of pooled cDNA were used to assess the amplification
efficiency of the primers and to establish the dynamic range of
cDNA concentration for amplification. SDS 2.4 software was
used for data collection, and the relative expression of the
mRNAs was determined with the comparative DDCt method.
Quantitative lipidomics
Lipid extraction for MS lipidomics
Mass spectrometry-based lipid analysis was performed by Lipotype
GmbH as described (Sampaio et al, 2011). Samples were spiked
with internal lipid standard mixture containing the following:
cardiolipin 16:1/15:0/15:0/15:0 (CL), ceramide 18:1;2/17:0 (Cer),
diacylglycerol 17:0/17:0 (DAG), hexosylceramide 18:1;2/12:0
(HexCer), lyso-phosphatidate 17:0 (LPA), lyso-phosphatidylcholine
12:0 (LPC), lyso-phosphatidylethanolamine 17:1 (LPE), lyso-phos-
phatidylglycerol 17:1 (LPG), lyso-phosphatidylinositol 17:1 (LPI),
lyso-phosphatidylserine 17:1 (LPS), phosphatidate 17:0/17:0 (PA),
phosphatidylcholine 17:0/17:0 (PC), phosphatidylethanolamine
17:0/17:0 (PE), phosphatidylglycerol 17:0/17:0 (PG), phosphatidyli-
nositol 16:0/16:0 (PI), phosphatidylserine 17:0/17:0 (PS), choles-
terol ester 20:0 (CE), sphingomyelin 18:1;2/12:0;0 (SM), and
triacylglycerol 17:0/17:0/17:0 (TAG). After CHCl3/MeOH extraction,
the organic phase was transferred to an infusion plate and dried in a
speed vacuum concentrator. The first step dry extract was resus-
pended in 7.5 mM ammonium acetate in chloroform/methanol/
propanol (1:2:4, V:V:V) and the second step dry extract in a 33%
ethanol solution of methylamine in chloroform/methanol
(0.003:5:1; V:V:V). All liquid handling steps were performed using
the Hamilton Robotics STARlet robotic platform with the Anti
Droplet Control feature for organic solvent pipetting.
MS data acquisition
Samples were analyzed by direct infusion on a Q Exactive mass
spectrometer (Thermo Scientific) equipped with a TriVersa Nano-
Mate ion source (Advion Biosciences). Samples were analyzed in
both positive and negative ion modes with a resolution of Rm/
z = 200 = 280,000 for MS and Rm/z = 200 = 17,500 for MS/MS
experiments in a single acquisition. MS/MS was triggered by an
inclusion list encompassing corresponding MS mass ranges scanned
in 1-Da increments. Both MS and MS/MS data were combined to
monitor CE, DAG, and TAG ions as ammonium adducts; PC, PC and
O-, as acetate adducts; and CL, PA, PE, PE O-, PG, PI, and PS as
deprotonated anions. MS only was used to monitor LPA, LPE, LPE
O-, LPI, and LPS as deprotonated anions; Cer, HexCer, SM, LPC and
LPC O- were used as acetate adducts.
Quantitative proteomics (iTRAQ)
Protein digestion
In solution digestion: After denaturation of protein with 8 M urea,
samples were reduced and alkylated with 10 mM DTT (1 h at 37°C)
and 50 mM iodoacetamide (1 h at room temperature), respectively.
Next, samples were diluted to reduce the urea concentration below
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1.4 M and digested using sequencing grade trypsin (Promega) over-
night at 37°C using a 1:5 (w/w) trypsin/protein ratio. Whole super-
natants were dried down and then desalted on OASIS C18 columns
(Waters) until the mass spectrometric analysis.
iTraq labeling and high-pH fractionation
The resultant peptide mixture from desalted protein tryptic digests
(100 µg) was dissolved in 30 µl of 0.5 M triethylammonium
bicarbonate (TEAB), pH 8, and labeled using the iTRAQ reagent
4plex Multi-plex kit (Applied Biosystems). Labeling was stopped
by the addition of 0.1% formic acid. The obtained “4plex-labeled
mixture” was analyzed by RP-LC-MS/MS to check the efficiency
of the labeling. The sample was then fractionated using the high-
pH, reversed-phase peptide fractionation kit (Pierce, Thermo
Scientific). The sample was re-swollen in 0.1% TFA and then
loaded onto an equilibrated, high-pH, reversed-phase fractionation
spin column. A step gradient of increasing acetonitrile concentra-
tions in a volatile high-pH solution was applied to the columns to
elute bound peptides into nine different fractions (5–80% acetoni-
trile) collected by centrifugation. The fractions obtained were
dried and stored until analysis by mass spectrometry for quan-
tification.
Quantitative analysis by RP-LC-MS/MS
The fractions were resuspended in 10 ll of 0.1% formic acid and
analyzed by RP-LC-MS/MS in an Easy-nLC II system coupled to an
ion trap LTQ-Orbitrap-Velos-Pro hybrid mass spectrometer (Thermo
Scientific, Waltham, Massachusetts, Estados Unidos). Peptides were
concentrated (on-line) by reverse phase chromatography using a
0.1 × 20 mm C18 RP precolumn (Proxeon) and then separated
using a 0.075 × 250 mm C18 RP column (Proxeon) operating at
0.3 ll/min. Peptides were eluted using a 90-min dual gradient from
5 to 25% solvent B in 68 min, followed by a gradient from 25 to
40% solvent B over 90 min (solvent A: 0.1% formic acid in water,
solvent B: 0.1% formic acid, 80% acetonitrile in water). ESI ioniza-
tion was performed using a Nano-bore emitters Stainless Steel ID
30 lm (Proxeon) interface. The instrument method consisted of a
data-dependent top-20 experiment with an Orbitrap MS1 scan at a
resolution (m/Dm) of 30,000, followed by 20 high energy collision
dissociation (HCD) MS/MS mass analysis in an Orbitrap at 7,500
(Dm/m) resolution. MS2 experiments were performed using HCD to
generate high resolution and high mass accuracy MS2 spectra. The
minimum MS signal for triggering MS/MS was set to 500. The lock
mass option was enabled for both MS and MS/MS mode, and the
polydimethylcyclosiloxane ions (protonated (Si(CH3)2O))6; m/z
445.120025) were used for internal recalibration of the mass spec-
tra. Peptides were detected in survey scans from 400 to 1,600 amu
(1 lscan) using an isolation width of 2 u (in mass-to-charge ratio
units), normalized collision energy of 40% for HCD fragmentation,
and dynamic exclusion applied during 30-s periods. Precursors of
unknown or +1 charge state were rejected.
Proteomic and lipidomic data analyses
Proteomics
Peptide identification from raw data was carried out using a
PEAKS Studio X search engine (Bioinformatics Solutions Inc.). A
database search was performed against uniprot-Mus
musculus.fasta (decoy-fusion database). The following constraints
were used for the searches: tryptic cleavage after Arg and Lys, up
to two missed cleavage sites, and tolerances of 20 ppm for
precursor ions and 0.05 Da for MS/MS fragment ions, and the
searches were performed allowing optional Met oxidation, Cys
carbamidomethylation, and iTRAQ reagent labeling at the N-
terminus and lysine residues. False discovery rates (FDRs) for
peptide spectrum matches (PSMs) were limited to 0.01. Only
those proteins with at least two distinct peptides being discovered
from LC/MS/MS analyses were considered reliably identified and
sent to be quantified. Quantitation of iTRAQ-labeled peptides was
performed with a PEAKS Studio X search engine. The 10LgP,
quality and reporter ion intensity were used for spectrum filter
and significance (ANOVA method) for protein filter. For protein
quantification, we considered protein groups for peptide unique-
ness and used only unique peptides, and the modified peptides
were excluded.
Lipidomics
Data were analyzed with lipid identification software LipidXplorer
(Lipotype). Only lipid identifications with a signal-to-noise ratio > 5
and a signal intensity 5-fold higher than that in corresponding blank
samples were considered for further data analysis.
Data availability
Skm and WAT iTRAQ proteomic data are available via ProteomeX-
change with identifier PRIDE PXD017621; http://www.ebi.ac.uk/
pride/archive/projects/PXD017621 (Skm), PXD017683; http://www.eb
i.ac.uk/pride/archive/projects/PXD017683 (Skm + HFD) and PXD0176
78; http://www.ebi.ac.uk/pride/archive/projects/PXD017678 (WAT).
Skm and WAT lipidomic data are available via Figshare: https://doi.
org/10.6084/m9.figshare.11872077.v1
Expanded View for this article is available online.
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